Egalet Guardian™ Technology
Abuse Deterrence Plus Precision Delivery
Egalet’s Guardian Technology was developed to provide peace of mind to physicians and patients by delivering commonly abused prescription medications in an abuse-deterrent form.
Abuse-Deterrent Features
Opioid analgesics developed using Guardian Technology are designed to deter common methods of abuse. Guardian Technology utilizes injection molding to create a hard matrix and shell that is designed to be difficult to crush, grind, chew, or dissolve and that turns to gel when exposed to water.
Precision Delivery
Guardian Technology is designed to deliver the active ingredient using a zero-order release profile (see Figure).1 This zero-order release profile is designed to deliver the active ingredient at a constant rate of release and with lower peak plasma levels (Cmax),1,2 to delay and reduce the potential reinforcing effects of the product when taken whole.3,4
Guardian Technology combines abuse-deterrent features with a precision zero-order delivery profile (see Figure).1,2
References
- Hemmingsen PH, Haahr AM, Gunnergaard C, Cardot JM. Development of a new type of prolonged release hydrocodone formulation based on Egalet® ADPREM technology using in vivo–in vitro correlation. Pharmaceutics. 2011;3(1):73-87.
- Siegel RA, Rathbone MJ. Overview of controlled release mechanisms. In: Siepmann J, Siegel R, Rathbone RA, eds. Fundamentals and Applications of Controlled Release Drug Delivery. New York: Springer Science+Business Media; 2012:19-43.
- Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R Jr. Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse deterrent formulations. Curr Pharm Des. 2012;18(37):6109-6115.
- Webster L. The question of opioid euphoria. Drug Discovery and Development. July 30, 2009. http://www.dddmag.com/articles/2009/07/question-opioid-euphoria. Accessed December 3, 2014.
Guardian Technology is a trademark of Egalet Corporation.